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Clinical InvestigationHistory of bleeding and outcomes with
apixaban versus warfarin in patients with
atrial fibrillation in the Apixaban for Reduction
in Stroke andOther Thromboembolic Events in
Atrial Fibrillation trial
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Frankfurt, Germany; Boston, MA; Temuco, Chile; IdiPaz Madrid, Spain; and Adelaide, AustraliaAims History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation (AF). We analyzed outcomes
in relation to history of bleeding and randomization in ARISTOTLE trial patients.
Methods and results The on-treatment safety population included 18,140 patients receiving at least 1 dose of study
drug (apixaban) or warfarin. Centrally adjudicated outcomes in relation to bleeding history were analyzed using a Cox
proportional hazards model adjusted for randomized treatment and established risk factors. Efficacy end points were analyzed
on the randomized (intention to treat) population. A bleeding history was reported at baseline in 3,033 patients (16.7%), who
more often were male, with a history of prior stroke/transient ischemic attack/systemic embolism and diabetes; higher
CHADS2 scores, age, and body weight; and lower creatinine clearance and mean systolic blood pressure. Major (but not
intracranial) bleeding occurred more frequently in patients with versus without a history of bleeding (adjusted hazard ratio
1.35, 95% CI 1.14-1.61). There were no significant interactions between bleeding history and treatment for stroke/systemic
embolism, hemorrhagic stroke, death, or major bleeding, with fewer outcomes with apixaban versus warfarin for all of these
outcomes independent of the presence/absence of a bleeding history.
Conclusion In patients with AF in a randomized clinical trial of oral anticoagulants, a history of bleeding is associated
with several risk factors for stroke and portends a higher risk of major—but not intracranial—bleeding, during anticoagulation.
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lA history of bleeding is important in decision making
for anticoagulation in atrial fibrillation (AF), as it may limit
the use of anticoagulants in favor of the less effective
antiplatelet agents or no antithrombotic agents.1 Both
approaches have been shown to be associated with
worse outcomes.2,3 A history of bleeding is the clinica
factor most commonly used in evaluating future bleeding
risk in patients with AF in predictive algorithms such as
the HEMORR2HAGES (Hepatic or Renal Disease, Ethano
Abuse, Malignancy, Older Age, Reduced Platelet Count or
Function, Re-Bleeding, Hypertension, Anemia, Genetic
Factors, Excessive Fall Risk and Stroke),4 HAS-BLED
(Hypertension, Abnormal Renal/Liver Function, Stroke
Bleeding History or Predisposition, Labile Internationa
Normalized Ratio, Elderly, Drugs/Alcohol),5 and ATRIA
(Anticoagulation and Risk Factors in Atrial Fibrillation)6
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patients with AF before the initiation of treatment.7,8
It is possible that a history of bleeding is associated with
a higher risk of future thromboembolic events, perhaps
as a result of lesser adherence to the prescribed
antithrombotic therapy or because of the overlap
between risk factors for bleeding and those for thrombo-
embolism in AF.
The ARISTOTLE trial9 compared apixaban with warfa-
rin in patients with AF at increased risk for stroke. Using
data from the 18,201 patients enrolled in ARISTOTLE, we
evaluated outcomes in relation to a history of bleeding
and randomization treatments. We hypothesized that a
history of bleeding is associated with future bleeding
events and, secondarily, to ischemic events. We also
assessed whether the favorable association of apixaban
versus warfarin with stroke and systemic embolism (SE),
hemorrhagic stroke, major bleeding, and death9 was
similar in patients with or without a history of bleeding.
Methods
The design and results of the ARISTOTLE trial have
been published previously (Lopes AHJ 2012 and Granger
NEJM 2011). The on-treatment safety population included
18,140 patients (of the 18,201 randomized in ARISTOT-
LE) who received at least 1 dose of study drug. Patients
were randomly assigned to treatment with either
apixaban 5 mg twice daily (2.5 mg twice daily with 2 of
the following: age ≥80 years, body weight ≤60 kg, or
creatinine ≥133 μmol/L) or warfarin (target international
normalized ratio 2.0-3.0, with a median time in therapeu-
tic range of 66%), for a median of 1.8 years. Patients were
excluded if they had an increased bleeding risk believed
to be a contraindication to oral anticoagulation (eg,
documented peptic ulcer disease within 6 months,
previous intracranial hemorrhage).
Bleeding history was captured in the screening case
report form as the answer to the question: “Does the
subject have a history of clinically relevant (CR) or
spontaneous bleeding?” with details collected about the
timing and the location of prior bleeding. The prior
bleeding events were subcategorized as history of major
bleeding, history of minor bleeding, and history of
gastrointestinal (GI) bleeding based on the information
on location of prior bleeding. Bleeding definitions used in
the trial are summarized in online Appendix Supplemen-
tary Table I. History of peptic ulcer disease and date were
also collected because this is a determinant of upper GI
bleeding and a frequent specific deterrent to the use of
anticoagulants.
Statistical analysis
Baseline characteristics for the 18,137 of 18,140
patients in the on-treatment population who had
nonmissing bleeding history were examined by groupaccording to bleeding history. Continuous variables were
presented as means and either SD or 95% CIs, with
between-group comparisons tested by t test. Categorical
variables were presented as counts and percentages and
compared by χ2 tests.
Analyses of bleeding end points were based on the
on-treatment population, including all randomized pa-
tients who received at least 1 dose of the study drug, and
included all events from receipt of the study drug until 2
days after the last dose. Primary and secondary efficacy
analyses included all randomized patients (intention to
treat) and included all events from randomization until
the efficacy cutoff date (predefined as January 30, 2011).
Outcomes in relation to study treatments and bleeding
history were analyzed using a Cox proportional hazards
model including treatment group, bleeding history group,
and treatment by bleeding history group interaction as
covariates. Hazard ratios (HRs) with 95% CI for treatment
comparisons were reported by bleeding history group,
regardless of the significance of interaction. The effect of
bleeding history was analyzed in Cox regression models
including bleeding history category and randomized
treatment as covariates and in models also adjusting for
prior warfarin/vitamin K antagonist (VKA) status; geo-
graphic region; age (continuous); sex; glomerular filtra-
tion rate according to the CKD-EPI formula (continuous);
smoking status; systolic blood pressure (BP) (continu-
ous); heart rate (continuous); AF type; diabetes; heart
failure; previous stroke/SE/transient ischemic attack
(TIA); hypertension, previous myocardial infarction
(MI); previous peripheral arterial disease/coronary artery
bypass grafting/percutaneous coronary interventions;
and treatment at randomization with aspirin, angioten-
sin-converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs), amiodarone, and statins. For
bleeding events, history of anemia, anemic at baseline
(defined as hemoglobin b13.0 g/dL in men and hemo-
globin b12.0 g/dL in women), hematocrit, chronic liver
disease, and use of nonsteroidal anti-inflammatory drugs
(NSAIDs) at randomization were also included. Restricted
cubic splines were used to allow for nonlinear relation-
ship between continuous variables and outcomes.
Event rates per 100 patient-years of follow-up were
reported, and Kaplan-Meier estimates of the cumulative
risk were calculated and plotted. All analyses were
performed using the SAS version 9.4 software (SAS
Institute, Inc, Cary, NC). A 2-sided P value of .05 was
considered statistically significant, and because all
analyses were exploratory, there were no adjustments
for multiple comparisons.
Results
Demographic and clinical characteristics
History of bleeding was reported in 3,033 (16.7%) of
the 18,137 on-treatment patients. Patients reporting a
Table I. Baseline demographic and clinical characteristics of
patients with and without a history of bleeding
aseline characteristic








n 3033 15,104 b.0001
Mean (SD) 70.9 (9.1) 68.7 (9.7)
eight
n 3026 15,051 b.0001
Mean (SD) 85.8 (21.2) 83.7 (20.6)
ale sex, n (%) 2048 (67.5%) 9696 (64.2%) .0005
egion, n (%)
Asia/Pacific 459 (15.1%) 2445 (16.2%)
Europe 915 (30.2%) 6398 (42.4%) b.0001
Latin America 480 (15.8%) 2978 (19.7%)
North America 1179 (38.9%) 3283 (21.7%)
alculated CrCL, mL/min
n 3025 15,038 .0007
Mean (SD) 77.4 (32.7) 79.6 (32.3)
evel of renal impairment, n (%)
Normal 1174 (38.7%) 6321 (41.8%) b.0001
Mild 1254 (41.3%) 6309 (41.8%)
Moderate 547 (18.0%) 2190 (14.5%)
Severe 50 (1.6%) 218 (1.4%)
Not reported 8 (0.3%) 66 (0.4%)
ystolic BP
n 3030 15,071 .0027
Mean (SD) 130.5 (17.1) 131.5 (16.2)
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Volume 175history of bleeding, compared with those with no
history of bleeding, were more often male (67.5% vs
64.2%, P b .0005), with a history of prior stroke/TIA/SE
(22.7% vs 18.8%, P b .0001) and diabetes (27.3% vs 24.5%,
P = .0010, with trends to longer diabetes duration for the
minority [37%] of patients having such information and a
significantly higher percentage of insulin use, altogether
suggesting a higher severity of diabetes); had higher
CHADS2 scores (CHADS2 N3: 35.2% vs 29.2%), age (mean
[SD] 70.9 [9.1] vs 68.7 [9.7], P b .0001), and body weight
(85.8 [21.2] vs 83.7 [20.6], P b .0001); had a lower
calculated creatinine clearance (77.4 [32.7] vs 79.6
[32.3], P = 0.0007) and mean systolic BP (130.5 [17.1]
vs 131.5 [16.2], P = .0027); and had a higher HAS-BLED
score, also here calculated without the component of
bleeding history. Such patients were also more frequently
reporting alcohol abuse and history of anemia and were
more frequently anemic at baseline (Table I).
Calcium-channel blockers and statins were used slightly
more, and NSAIDs and proton pump inhibitors were used
substantially more in patients with versus those without a
history of bleeding. Conversely, ACE inhibitors, amioda-
rone, and digoxin were used slightly less in patients with
versus those without a history of bleeding (Table II).
Specifically, however, the use of aspirin in patients with a
history of bleeding was similar (30.3%), compared with
those without (31.0%, P = .4222).rior stroke/TIA/SE, n (%) 690 (22.7%) 2833 (18.8%) b.0001
HF within 3 m or LVEF
≤40%, n (%)
977 (32.2%) 5457 (36.1%) b.0001
HF within 3 m, n (%) 818 (27.0%) 4708 (31.2%) b.0001
iabetes mellitus, n (%) 828 (27.3%) 3697 (24.5%) .001
sulin at randomization 168 (5.5%) 657 (4.3%) .0041
HADS2 score, n (%)
≤1 953 (31.4%) 5214 (34.5%) b.0001
2 1012 (33.4%) 5479 (36.3%)
≥3 1068 (35.2%) 4411 (29.2%)
AS-BLED score†, n (%)
≤1 1727 (56.9%) 9875 (65.4%) b.0001
2 1096 (36.1%) 4459 (29.5%)
≥3 210 (6.9%) 770 (5.1%)





2247 (74.1%) 8127 (53.8%) b.0001
Warfarin/VKA naive 786 (25.9%) 6977 (46.2%)
lcohol abuse, n (%) 101 (3.3%) 352 (2.3%) .0013
istory of anemia, n (%) 474 (15.6%) 769 (5.1%) b.0001
nemic at baseline, n (%) 460 (15.2%) 1822 (12.1%) b.0001
o statistically significant differences (P N .05) between groups according to history of
leeding were found regarding type of AF and hypertension.
bbreviations: CHF, Congestive heart failure; CrCl, creatinine clearance; LVEF, left
entricular ejection fraction, SD, standard deviation; TIA, transient ischemic attack;
KA, vitamin K antagonist.
P value is for the comparison between groups according to history of bleeding and is
ased on the χ2 test for categorical variables and t test for continuous variables.
Mean (SD) for HAS-BLED score was calculated excluding labile international
ormalized ratio. Summary and χ2 test comparing groups across HAS-BLED score
ategories were also excluding history of CR or spontaneous bleeding.Outcomes in patients with or without a history of
bleeding
Of the primary and secondary efficacy/safety events
assessed in the ARISTOTLE trial (as detailed in Granger
et al9 and online Appendix Supplementary Table I), a
history of CR or spontaneous bleeding was associated
with a 35% increase in risk for major bleeding (adjusted
HR 1.35, 95% CI 1.14-1.61) and a 48% increase in risk for
major bleeding/CR nonmajor bleeding (adjusted HR 1.48,
95% CI 1.31-1.68). Other types of bleeding not included
in the primary safety end points, that is, Global Use of
Strategies to Open Occluded Coronary Arteries (GUSTO)
mild bleeding and International Society on Thrombosis
and Haemostasis (ISTH) minor bleeding, were more
frequent, and the risk was statistically higher in patients
with a history of bleeding (Table III). However, a history
of previous bleeding did not significantly entail a higher
risk of hemorrhagic stroke or intracranial bleeding during
the trial (Table III). In addition, a history of bleeding was
not associated with an increased risk of stroke (Table III).
Out of the broad category of history of clinically
significant or spontaneous bleeding (online Appendix
Supplementary Table I), the ARISTOTLE data base
captured a distinction between history of major and
history of minor bleeding. A history of major bleeding
(online Appendix Supplementary Table II), for which we






























Table II. Differential treatment characteristics (medications) at
randomization of patients with or without a previous history of
bleeding
Drug
History of CR or spontaneous
bleeding?
P⁎Yes (n = 3033) No (n= 15,104)
ACE inhibitor or ARB 2080 (68.6%) 10,709 (70.9%) .0105
Amiodarone 282 (9.3%) 1764 (11.7%) .0002
Aspirin 919 (30.3%) 4688 (31.0%) .4222
Digoxin 931 (30.7%) 4948 (32.8%) .0267
Calcium-channel blocker 1099 (36.2%) 4446 (29.4%) b.0001
Statins 1502 (49.5%) 5938 (39.3%) b.0001
NSAIDs 419 (13.8%) 1098 (7.3%) b.0001
Proton pump inhibitors 668 (22.0%) 1868 (12.4%) b.0001
Values are presented as number (percentage). No statistically significant differences
(p-value N0.05) between groups according to history of bleeding were found
regarding treatment with clopidogrel, aspirin and beta blockers at randomization.
⁎ P value is based on the χ2 test.
178 De Caterina et al
American Heart Journal
May 2016associated with a significantly higher risk of any type of
future bleeding. However, a history of major bleeding had
HR estimates for future major bleeding and major/CR
bleeding that were similar to the HRs that history of CR or
spontaneous bleeding had for future bleeds (1.28 vs 1.35
for future major bleeds, 1.36 vs 1.48 for major or CR
bleed), although wider CIs for those estimates due to the
small number of patients with such a history of major
bleeding.
For a history of minor bleeding (n = 2,880), results were
similar to the results for the broad category of history of
clinically significant or spontaneous bleeding (online
Appendix Supplementary Table III).
Outcomes in patients with or without a history of GI
bleeding
A history of GI bleeding was associated with an
increased risk of bleeding during the trial: major bleeding
(adjusted HR 1.97 [95% CI 1.28-3.02]) or major or CR
nonmajor bleeding (adjusted HR 1.79 [95% CI 1.29-2.50]).
Of note, a history of previous GI bleeding was not
associated with the use of aspirin at randomization
(28.5% used aspirin in the group with history of GI
bleeding vs 30.9% in the group without a history).
Outcomes in patients with or without a history of
bleeding by treatment group
Despite higher rates of major bleeding in patients with
a history of bleeding, we found no significant differences
in the relative efficacy of apixaban and warfarin as a
function of the presence or absence of a history of
previous bleeding. There were no significant (P N .05)
interactions between bleeding history and treatment in
relation to outcomes for stroke/SE, hemorrhagic stroke,
death, or major bleeding. The event rates for theoutcomes of stroke/SE, hemorrhagic stroke, death, or
major bleeding were lower in patients receiving apixaban
as compared with those receiving warfarin. In particular,
despite a history of any previous CR or spontaneous
bleeding being associated with more major bleeding
occurring consistently throughout the trial, apixaban was
consistently associated with lower rates of major bleeding
compared with warfarin in both patients with and
without a history of bleeding (Figure 1D). The only
exception was the category of major/CR nonmajor
bleeding, for which the interaction P value was of
borderline significance (with a lower HR for apixaban vs
warfarin for this outcome in patients without versus
those with a history of bleeding) (Figure 2). We found no
significant interaction of treatment with history of GI
bleeding or history of major bleeding. For history of
minor bleeding, there was a significant interaction for
major/CR nonmajor bleeding, consistent with the overall
history of CR or spontaneous bleeding (with a lower HR
for apixaban vs warfarin for this outcome in patients
without vs those with a history of bleeding) (online
Appendix Supplementary Tables IV to VII).Discussion
This study shows that, in patients with AF who were
selected by their physicians for enrollment in ARISTOT-
LE, a history of bleeding was associated with several
clinical risk factors for stroke and bleeding and—the main
clinical thrust of the present investigation—with a higher
risk of subsequent bleeding during anticoagulation. A
history of bleeding did not, however, translate into an
increased risk of intracranial hemorrhage or any throm-
boembolic complications or death. In addition, this study
shows that the benefits of apixaban over warfarin were
consistent with regard to stroke/SE, intracranial hemor-
rhage, mortality, and major bleeding, irrespective of the
bleeding history. Novelties of this study are a careful
dissection of the impact of history of bleeding on future
outcomes and an assessment of the similar impact of
apixaban versus warfarin on outcomes, independent of
the bleeding history.
A history of bleeding is an important element in the
medical history of a patient with AF when his/her
candidacy for life-long oral anticoagulation is being
considered and has been found to be a clear deterrent to
the initiation or continuation of oral anticoagulation in
several reports.10-13 A history of bleeding is also likely to
explain the still large underutilization of antithrombotic
therapy or antiplatelet therapy in AF.14 Although major
current guidelines7,8 do not discourage the use of antic-
oagulation in patients with risk factors for bleeding, of
which a history of bleeding is a common component,4-6
they do encourage evaluation of the risk of bleeding to
implement special surveillance protocols. However, the
association between a history of bleeding and the risk for






Events Adjusted HR (95% CI)
P⁎(%/y) Yes vs no
Stroke or SE No 15,156 397 (1.4)
Yes 3040 80 (1.5) 0.97 (0.75-1.24) .7791
Hemorrhagic stroke No 15,156 101 (0.4)
Yes 3040 17 (0.3) 0.88 (0.52-1.49) .6215
Death No 15,156 1045 (3.7)
Yes 3040 227 (4.1) 1.08 (0.93-1.25) .3274
Cardiovascular death No 15,156 537 (1.9)
Yes 3040 115 (2.1) 1.14 (0.93-1.41) .2124
MI No 15,156 150 (0.5)
Yes 3040 42 (0.8) 1.05 (0.74-1.50) .7722
Major bleeding No 15,104 602 (2.4)
Yes 3033 186 (3.8) 1.35 (1.14-1.61) .0008
Major or CR nonmajor bleeding No 15,104 1124 (4.5)
Yes 3033 365 (7.8) 1.48 (1.31-1.68) b.0001
GUSTO severe bleeding No 15,104 207 (0.8)
Yes 3033 45 (0.9) 1.11 (0.79-1.55) .5629
GUSTO moderate/severe bleeding No 15,104 416 (1.6)
Yes 3033 110 (2.2) 1.11 (0.89-1.39) .3487
GUSTO mild bleeding No 15,104 1851 (7.7)
Yes 3033 618 (14.2) 1.60 (1.46-1.77) b.0001
ISTH minor bleeding No 15,104 1265 (5.2)
Yes 3033 424 (9.3) 1.58 (1.41-1.78) b.0001
Intracranial bleeding No 15,104 147 (0.6)
Yes 3033 27 (0.5) 0.90 (0.59-1.36) .6027
Cox proportional hazards model adjusted for randomized treatment, geographic region, prior VKA status, and established risk factors—age (continuous); sex; glomerular filtration
rate CKD-EPI (continuous); smoking status; systolic BP (continuous); heart rate (continuous); AF type; diabetes; heart failure; previous stroke/SE/TIA; hypertension; previous MI;
previous peripheral arterial disease/coronary artery bypass grafting/percutaneous coronary interventions; and treatment at randomization with aspirin, ACE inhibitors or ARBs,
amiodarone, and statins. For bleeding events, history of anemia, anemia at baseline, chronic liver disease, hematocrit, and use of NSAIDS at randomization were also included.
Hazard ratios for comparisons bleeding history (yes vs no).
⁎ P value for effect of bleeding history.
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Volume 175future bleeding as well as the risk for future ischemic
outcomes is largely unknown. In theory, a history of
bleeding, because it may prompt health care providers to
underdose anticoagulants or avoid them altogether, might
translate into an increased risk of ischemic events, as clearly
shown in the setting of acute coronary syndromes.15 Our
study specifically addressed the unmet need of assessing
the prognostic implications of a history of bleeding and
distinguishing between a history of any bleeding and a
history of major, minor, or GI bleeding.
We found that patients with a history of bleeding have
baseline characteristics different from patients without
such a history, being—as expected—older, more fre-
quently with impaired renal function or diabetes and with
features of higher diabetes severity; more often, they
were also anemic at baseline or with a history of anemia
or prior stroke and more frequently reporting alcohol
abuse, but also with lesser prevalence in Europe. In
comparing such baseline characteristics (as reported in
Tables I and II) with those of patients who actually bled
(ISTH major bleeding) during the course ARISTOTLE trial
while on anticoagulants, on which we have also reported
recently16 (see Table I in that study), most of such
characteristics are similar. It seems, therefore, thatbaseline characteristics of previous bleeders and of
bleeders on anticoagulants are relatively similar.
We found that a history of bleeding translates into more
future bleeding episodes. Importantly, a higher risk of
bleeding also occurs in the presence of a history of minor
bleeding. On the contrary, history of major bleeding (for
which data are scarce) was not found to be such a
predictor, but this may simply be due to the statistical
uncertainty of the estimates due to the small number of
major bleeding observed, as the HRs for the predictive
ability of a history of minor and major bleeding appear to
be quite similar. These findings imply that not only
previous major bleeding, but also previous minor
bleeding should be incorporated into scores for predict-
ing the risk of future bleeding events.4-6 This is currently
the case for the ATRIA bleeding risk score,6 but not for
the HEMORR2HAGES score, in which the severity of
previous bleeding is not specified,4 or for the HAS-BLED
score, which only takes previous major bleeding into
account.5 Currently, we do not know what subtype of
minor bleeding in the patients' medical history is really
predictive of future bleeding events. Such additional
information may be important for improving bleeding
scores in the future.
Figure 1
Kaplan-Meier curves depicting the accumulation of events as a function of time, divided according to the presence (continuous line) or absence of a
history of bleeding (dotted line) and of the randomized treatment (apixaban in blue) or warfarin (red). A, Stroke and SE. B, Hemorrhagic stroke. C,
Death. D, Major bleeding.
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future bleeding outcomes in our study remains signifi-
cant independent of the presence of anemia at baseline,
with P value for interaction of bleeding history and being
anemic at baseline always nonsignificant (P N .05). This is
noteworthy, in the light of our recent report on the
prognostic role of anemia in bleeding (and mortality, but
not stroke), in the ARISTOTLE cohort.17 We have also
recently reported on a characterization ofmajor bleeding
in the trial based on the components of the major
bleeding definition; explored major bleeding by loca-
tion; defined 30-day mortality after a major bleedingevent; and identified factors associated with major
bleeding.16 In that article, we have reported that,
compared with warfarin, apixaban was associated with
fewer intracranial hemorrhages, less adverse conse-
quences after extracranial hemorrhage, and a 50%
reduction in fatal consequences at 30 days in cases of
major hemorrhage. That article also found that previous
hemorrhage was a predictor of future bleeding.16 That
article, however, did not report on the implications of a
bleeding history for subsequent types of bleeding and for
ischemic events, which is, therefore, the aim of the
current study.
Figure 2
Bleeding outcomes in ARISTOTLE in relation to randomized treatment and absence or presence of a history of CR or spontaneous bleeding. No
significant interaction of treatment with history of any type of bleeding examined is found, with the exception of a marginally significant interaction
for the cluster of major/CR nonmajor bleeding.
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valvular AF, an analysis of predictors of bleeding has also
been done. Here increasing age, baseline diastolic BP≥90
mm Hg, history of chronic obstructive pulmonary disease
or GI bleeding, prior acetylsalicylic acid use, and anemia
were independently associated with major bleeding risk.
18 Such data, therefore, reporting that a history of GI
bleeding—in a completely independent study cohort—
predicts future bleeding reinforce and complement data
here presented. Those data were, however, only related
to history of GI bleeding.
We found that a history of bleeding (of any kind) is not
associated with an increased risk of the most ominous
complication of anticoagulant therapy, namely, intracra-
nial hemorrhage. Possible reasons for this are (1) the
rarity of such condition; (2) the exclusion of patients with
previous intracranial hemorrhage from the trial9,19; and/
or (3) the etiology of intracranial hemorrhage, different
from that of (major or minor) extracranial bleeding.20,21
We also found no association between a history of
bleeding and the risk of ischemic events, including
ischemic stroke. One could expect a higher risk of strokein these patients because there could be a tendency to
undertreat or underdose them. It is possible that
participation in a clinical trial has protected these patients
from being undertreated or underdosed. Real-world data
on this point would be, therefore, important to confirm
or not such data. Should these be confirmed, history of
bleeding would appear as a main discriminating factor
between bleeding and thrombotic risks and lend support
to the suggestion to start anticoagulant therapy in most
patients with nonvalvular AF, irrespective of the bleeding
risk assessment.7,22 This would be even more supported
by the use of NOACs, given that the net clinical benefit
from starting a non-vitamin K antagonist oral anticoagu-
lant (NOAC) in such patients is largely favorable
compared with VKAs and particularly favorable with
apixaban.23
Indeed, we found an overall benefit of apixaban over
warfarin, irrespective of the presence or absence of a
history of bleeding. We found no significant interaction of
treatment (apixaban vs warfarin) with history of major
bleeding (online Appendix Supplementary Table V), minor
bleeding (online Appendix Supplementary Table VI), or GI
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May 2016bleeding (online Appendix Supplementary Table VII). In
other words, the prognostic impact of history of bleeding
on major, minor, or GI bleeding was not significantly
different for the patients being on apixabanorwarfarin. For
history of minor bleeding, there was one significant
interaction for the outcome of major/CR nonmajor
bleeding, suggesting that the impact of history of minor
bleeding might be prognostically more relevant in predict-
ing major/CR nonmajor bleeding in patients treated with
apixaban than in those treated with warfarin (online
Appendix Supplementary Table VI). Previous reports of the
ARISTOTLE study did not report whether the benefits of
apixaban versus warfarin are consistent with regard to
stroke/SE, intracranial hemorrhage, mortality, and major
bleeding, irrespective of the bleeding history. In that, this
information now provided is another novelty of our study.
Indeed, by knowing that history of bleeding predicts future
bleeding, then physicians, by using this knowledge, may
choose among the various anticoagulant options now
available, and select drugs associated with less bleeding
compared with warfarin, such as apixaban.
In conclusion, this study shows that a history of even
minor bleeding, including GI bleeding, is a risk factor for
all future bleeding events, with the notable exception of
intracranial hemorrhage. A history of bleeding does not
appear to be associated with the risk of subsequent
ischemic events. Finally, the overall better efficacy and
safety of apixaban versus warfarin demonstrated in the
ARISTOTLE trial appears to apply broadly to both
patients with and without a history of bleeding. This
information is important information able to inform
physicians' behavior in prescribing anticoagulants for
nonvalvular AF.Disclosures
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